FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022
We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Teva sues ex-exec romantically involved with Apotex’s CEO; Pfizer bids adieu to Brazil`s Teuto
This week, Phispers brings you two tales
of alleged misuse of information involving former employees
FDA reorganizes inspection staff; Thermo Fisher buys Patheon for $ 5.2 billion
This week in Phispers, read about the extortion cyberattack and how it impacted hospitals in the UK.